CD8 cells of patients with diffuse cutaneous leishmaniasis display functional exhaustion: The latter is reversed, in vitro, by TLR2 agonists

PLoS Neglected Tropical Diseases

Volumn 4, Issue 11, 2010, Pages

  Hernández Ruiz, Joselín ^a   Salaiza Suazo, Norma ^a   Carrada, Georgina ^b   Escoto, Sofía ^a   Ruiz Remigio, Adriana ^a   Rosenstein, Yvonne ^c   Zentella, Alejandro ^d,e   Becker, Ingeborg ^a  

^a HOSPITAL GENERAL DE MÉXICO   (Mexico)

^b UNIVERSIDAD JUÁREZ AUTÓNOMA DE TABASCO   (Mexico)

^c INSTITUTO DE BIOTECNOLOGÍA   (Mexico)

^d SECRETARÍA DE SALUD   (Mexico)

^e INSTITUTO DE INVESTIGACIONES BIOMÉDICAS   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMONY DERIVATIVE; LIPOPHOSPHOGLYCAN; PAM3CYS; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; GLYCOSPHINGOLIPID; TLR2 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 2;

ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; BIOPSY; CD8+ T LYMPHOCYTE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEISHMANIA MEXICANA; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MALE; NONHUMAN; SKIN LEISHMANIASIS; T LYMPHOCYTE ACTIVATION; ADULT; CELL CULTURE; DRUG POTENTIATION; IMMUNOLOGY; LEISHMANIA; MIDDLE AGED; PARASITOLOGY; PHYSIOLOGY;

ADULT; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; FEMALE; GLYCOSPHINGOLIPIDS; HUMANS; LEISHMANIA; LEISHMANIASIS, DIFFUSE CUTANEOUS; MALE; MIDDLE AGED; TOLL-LIKE RECEPTOR 2; YOUNG ADULT;

EID: 78649797454     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000871     Document Type: Article

References (40)

1. Murray H, Berman J, Davies C, Saravia N (2005) Advances in leishmaniasis. Lancet 366: 1561-1577.
2. Becker I, Volkow P, Velasco-Castrejon O, Salaiza-Suazo N, Berzunza-Cruz M, et al. (1999) The efficacy of pentamidine combined with allopurinol and immunotherapy for the treatment of patients with diffuse cutaneous leishmaniasis. Parasitol Res 85: 165-170.
3. Convit J, Ulrich M, Polegre MA, Avila A, Rodriguez N, et al. (2004) Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized Leishmania promastigotes and Bacillus Calmette-Guerin: preliminary report. Mem Inst Oswaldo Cruz 99: 57-62.
4. Badaro R, Johnson WD (1993) The role of interferon in the treatment of visceral and diffuse cutaneous leishmaniasis. J Infect Dis 167(S1): S13-S17.
5. Sacks D, Noben-Trauth N (2002) The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2: 845-858.
6. Becker I, Salaiza N, Aguirre M, Delgado J, Carrillo-Carrasco N, et al. (2003) Leishmania lipophosphoglycan (LPG) activates NK cells through toll-like receptor-2. Mol Biochem Parasitol 130: 65-74.
7. Liese J, Schleicher U, Bogdan C (2008) The innate immune response against Leishmania parasites. Immunobiology 213: 377-387.
8. Kavoosi G, Ardestani SK, Kariminia A (2009) The involvement of TLR2 in cytokine and reactive oxygen species (ROS) production by PBMCs in response to Leishmania major phosphoglycans (PGs). Parasitology 136: 1193-1199.
9. Bogdan C (2007) Phagocyte effector functions against Leishmania parasites. In: Denkers EY, Gazzinelli RT, eds. Protozoans in Macrophages. Austin, TX: Landes Bioscience. pp 193-206.
10. Ruiz JH, Becker I (2007) CD8 cytotoxic T cells in cutaneous leishmaniasis. Parasite Immunol 29: 671-678.
11. Salaiza-Suazo N, Volkow P, Tamayo R, Moll H, Gillitzer R, et al. (1999) Treatment of two patients with diffuse cutaneous leishmaniasis caused by Leishmania mexicana modifies the immunohistological profile but not the disease outcome. Trop Med Int Health 4: 801-811.
12. Shin H, Wherry EJ (2007) CD8 T cell dysfunction during chronic viral infection. Curr Opin Immunol 19: 408-415.
13. + T cell exhaustion. J Immunol 182: 6697-6708.
14. Barber D, Wherry E, Masopust D, Zhu B, Allison J, et al. (2006) Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439: 682-687.
15. Day C, Kaufmann D, Kiepiela P, Brown J, Moodley E, et al. (2006) PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443: 350-354.
16. + T cells and confers protection against Leishmania donovani infections. PLoS Pathog 5(5): e1000431. doi:10.1371/journal.ppat.1000431.
17. Nakamoto N, Kaplan D, Coleclough J, Li Y, Valiga M, et al. (2008) Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology 134: 1927-1937.
18. Wong R, Smith K, Tam V, Pagarigan R, Meisenburg B, et al. (2009) TLR-9 signaling and TCR stimulation co-regulate CD8 T cell- associated PD-1 expression. Immunol Let 127: 60-67.
19. Quigley M, Martinez J, Huang X, Yang Y (2009) A critical role for direct TLR2- MyD88 signaling in CD8 T-cell clonal expansion and memory formation following vaccinia viral infection. Blood 113: 2256-2264.
20. Whiteside T, Bryant J, Day R, Herberman R (1990) Natural killer cytotoxicity in the diagnosis of immune dysfunction: criteria for a reproducible assay. J Clin Lab Anal 4: 102-114.
21. Derby E, Reddy V, Kopp W, Nelson E, Baseler M, et al. (2001) Three-color flow cytometric assay for the study of the mechanisms of cell-mediated cytotoxicity. Immunol Lett 78: 35-39.
22. Lyons AB (2000) Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods 243: 147-154.
23. Chávez-Galán L, Arenas-Del Angel MC, Zenteno E, Chávez R, Lascurain R (2009) Cell death mechanisms induced by cytotoxic lymphocytes. Cell Mol Immunol 6: 15-25.
24. Bogdan C (2001) Nitric oxide and the immune response. Nat Immunol 2: 907-916.
25. Müller I, Pedrazzini T, Kropf P, Louis J, Milon G (1991) Establishment of resistance to Leishmania major infection in susceptible BALB/c mice requires parasite-specific CD8+ T cells. Int Immunol 3: 587-597.
26. + T cells. Parasite Immunol 25: 559-567.
27. Reithinger R, Dujardin J, Louzir H, Pirmez C, Alexander B, et al. (2007) Cutaneous leishmaniasis. Lancet Infect Dis 7: 581-596.
28. + cells from lesions of patients with localized cutaneous leishmaniasis. Braz J Med Biol Res 33: 317-325.
29. Moore K, Matlashewski G (1994) Intracellular infection by Leishmania donovani inhibits macrophage apoptosis. J Immunol 152: 2930-2937.
30. Donovan M, Maciuba B, Mahan C, McDowell M (2009) Leishmania infection inhibits cycloheximide-induced macrophage apoptosis in a strain-dependent manner. Exp parasitol 123: 58-64.
31. Valdés-Reyes L, Argueta J, Morán J, Salaiza N, Hernández J, Berzunza M, et al. (2009) Leishmania mexicana: inhibition of camptothecin-induced apoptosis of monocyte-derived dendritic cells. Exp Parasitol 121: 199-207.
32. Aga E, Katschinski DM, van Zandbergen G, Laufs H, Hansen B, et al. (2002) Inhibition of the spontaneous apoptosis of neutrophil granulocytes by the intracellular parasite Leishmania major. J Immunol 169: 898-905.
33. Winau F, Weber S, Sad S, de Diego J, Hoops S, et al. (2006) Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis. Immunity 24: 105-117.
34. Bousoffara T, Louzir H, Salah B, Dellagi K (2004) Analysis of granzyme B activity as a surrogate marker of Leishmania-specific cell-mediated cytotoxicity in zoonotic cutaneous leishmaniasis. J Infect Dis 189: 1265-1273.
35. Rogers KA, Titus RG (2004) The human cytokine response to Leishmania major early after exposure to the parasite in vitro. J Parasitol 90: 557-563.
36. Rogers KA, Titus RG (2004) Characterization of the early cellular immune response to Leishmania major using peripheral blood mononuclear cells from Leishmania-naive humans. Am J Trop Med Hyg 71: 568-576.
37. Zajac AJ, Blattman J, Murali-Krishna K, Sourdive D, Suresh M, et al. (1998) Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 188: 2205-2213.
38. Wherry E, Blattman J, Murali-Krishna K, van der Most R, Ahmed R (2003) Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 77: 4911-4927.
39. Kabelitz D (2007) Expression and function of Toll-like receptors in T lymphocytes. Curr Opin Immunol 19: 39-45.
40. van Maren W, Jacobs J, de Vries I, Nierkens S, Adema G (2008) Toll-like receptor signalling on Tregs: to suppress or not to suppress? Immunology 124: 445-452.